See more : Boosh Plant-Based Brands Inc. (VEGI.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Asep Medical Holdings Inc (SEPSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Asep Medical Holdings Inc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BICO Group AB (publ) (CLLKF) Income Statement Analysis – Financial Results
- Optima Health plc (OPT.L) Income Statement Analysis – Financial Results
- Newpoint Financial Corp. (NPFC) Income Statement Analysis – Financial Results
- Kingboard Laminates Holdings Limited (1888.HK) Income Statement Analysis – Financial Results
- iSTART-TEK INC. (6786.TWO) Income Statement Analysis – Financial Results
Asep Medical Holdings Inc (SEPSF)
About Asep Medical Holdings Inc
Asep Medical Holdings Inc., through its subsidiary, ASEP Medical Inc. focuses on developing an early diagnostic tool for Sepsis and peptide therapeutic treatments for multiple applications. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to Asep Medical Holdings Inc. Asep Medical Holdings Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 21.14K | 0.00 | 0.00 | 0.00 | 61.17K |
| Cost of Revenue | 134.88K | 155.40K | 177.18K | 26.45K | 55.01K |
| Gross Profit | -113.74K | -155.40K | -177.18K | -26.45K | 6.16K |
| Gross Profit Ratio | -538.03% | 0.00% | 0.00% | 0.00% | 10.07% |
| Research & Development | 678.54K | 615.04K | 73.60K | 0.00 | 0.00 |
| General & Administrative | 4.23M | 2.54M | 1.73M | 1.65K | 6.51K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.23M | 2.54M | 1.73M | 1.65K | 6.51K |
| Other Expenses | 2.70M | -814.00 | -25.61K | 0.00 | 0.00 |
| Operating Expenses | 7.61M | 5.44M | 1.98M | 1.65K | 6.51K |
| Cost & Expenses | 7.74M | 5.44M | 1.98M | 28.10K | 61.53K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 270.00 | 814.00 | 102.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.29M | 1.28M | 177.18K | 28.10K | 353.00 |
| EBITDA | -8.14M | -3.33M | -1.92M | 0.00 | 0.00 |
| EBITDA Ratio | -38,486.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.72M | -5.44M | -1.98M | -28.10K | -353.00 |
| Operating Income Ratio | -36,524.42% | 0.00% | 0.00% | 0.00% | -0.58% |
| Total Other Income/Expenses | -1.71M | -403.73K | -289.55K | 0.00 | 0.00 |
| Income Before Tax | -9.43M | -5.85M | -2.34M | -28.10K | -353.00 |
| Income Before Tax Ratio | -44,609.81% | 0.00% | 0.00% | 0.00% | -0.58% |
| Income Tax Expense | 0.00 | -89.10K | -41.48K | 0.00 | 0.00 |
| Net Income | -8.23M | -4.52M | -2.20M | -28.10K | -353.00 |
| Net Income Ratio | -38,918.30% | 0.00% | 0.00% | 0.00% | -0.58% |
| EPS | -0.13 | -0.08 | -0.04 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.08 | -0.04 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 62.24M | 56.20M | 56.13M | 14.91M | 14.91M |
| Weighted Avg Shares Out (Dil) | 62.24M | 56.20M | 56.13M | 14.91M | 14.91M |
Asep Medical Featured in National Documentary
Asep was selected to be a part of a special series titled Empowered, Hosted by Meg Ryan, focusing on science, technology and medicine leaders. VANCOUVER, BC , Aug. 1, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the...
Asep Joint Venture Company, SepSMART, obtains Business License and is Formally Registered in China
VANCOUVER, BC , April 5, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that its joint venture company with leading Chinese biotech company Sansure Biotech Inc. ("Sansure"), Hunan Sanway SepSMART...
Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
CLICK HERE TO REGISTER VANCOUVER, BC , March 18, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that it is holding an online webinar on March 22, 2024,...
Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
VANCOUVER, BC , March 13, 2024 /PRNewswire/ - In a recent presentation to the US Biophysical Society in Philadelphia 1, Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) CEO Dr. Bob Hancock announced how...
Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
VANCOUVER, BC , Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis...
ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT
VANCOUVER, BC , Dec. 28, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, further to its news release of December 18, 2023, it has issued 3,915,930 units...
Asep Medical Holdings Inc. is Granted Patent Approval for its AI-based Sepsis Diagnostic Technology in the US
VANCOUVER, BC , Nov. 24, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that the Company's AI-based sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in the United...
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.
VANCOUVER, BC , Nov. 21, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that, through its subsidiary Sepset Biosciences Inc. ("Sepset"), it has signed a definitive joint venture...
Asep Inc. in Final Stage of Approval Process for NASDAQ Listing Registration Statement
VANCOUVER, BC , Nov. 17, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it is in the final stage of its approval process for the draft registration...
Another Breakthrough-- Asep Inc.'s A.I.-Based Sepsis Technology Identifies COVID-19 Severity from a Blood Sample
A recent study led by Asep Inc.'s Founder, Chair and CEO, Dr. Robert E. W. Hancock, concludes that there is hope for improved clinical management of COVID-19 patients by better assessing the severity of sepsis, a deadly disease that impacts many COVID-19 patients.
Source: https://incomestatements.info
Category: Stock Reports